bluebird bio Manufacturing
Durham, NC
Program data pending ClinicalTrials.gov matching
· Last scored 2026-04-02
78.5
Signal Score
○ FDA Inspections
○ Clinical Trials
✓ SEC Filings (11)
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: bluebird bio Manufacturing
- Signal Score
- 78.5/100 (as of 2026-04-02)
- Quality Compliance
- Assessment pending
- Headquarters
- Durham, NC
- Modalities
- Lentiviral, Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesLentiviral, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
86.0
Publicly traded — financial transparency
Strong industry presence in SEC filings (429 mentions)
Multiple manufacturing risk factors in SEC filings
Source: SEC EDGAR, press monitoring
11 SEC filings with industry mentions on record
SEC Filings11 with industry mentions
Publicly traded — financial transparency
Strong industry presence in SEC filings (429 mentions)
Multiple manufacturing risk factors in SEC filings
Capacity
71.0
10 facility investment mentions in SEC filings
Sites: Durham, NC
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
10 facility investment mentions in SEC filings
Financial Intelligence
"These forward-looking statements include, but are not limited to, statements about:
•
our entrance into an Agreement and Plan of Merger (the "Merger Agreement") with Beacon Parent Holdings, L.P., a Delaware limited partnership ("Parent"), and Beacon Merger Sub, Inc., a Delaware corporation ("Merger Sub"), including our beliefs about the potential benefits of the transaction contemplated by the Merger Agreement; and the planned completion and timing of the transaction contemplated by the Merger A"
"•
Among other potential adverse events, insertional oncogenesis is a significant risk of gene therapies using viral vectors that can integrate into the genome."
"The Company is a biotechnology company committed to commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector ("LVV") gene addition platform."
"These forward-looking statements include, but are not limited to, statements about:
•
our entrance into an Agreement and Plan of Merger (the "Merger Agreement") with Beacon Parent Holdings, L.P., a Delaware limited partnership ("Parent"), and Beacon Merger Sub, Inc., a Delaware corporation ("Merger Sub"), including our beliefs about the potential benefits of the transaction contemplated by the Merger Agreement; and the planned completion and timing of the transaction contemplated by the Merger A"
"•
Among other potential adverse events, insertional oncogenesis is a significant risk of gene therapies using viral vectors that can integrate into the genome."
"Business
Overview
We are a biotechnology company committed to commercializing potentially curative gene therapies for severe genetic diseases based on our proprietary lentiviral vector (“LVV”) gene addition platform."
"These forward-looking statements include, but are not limited to, statements about:
•
our plans and expectations regarding our commercialization activities for SKYSONA, ZYNTEGLO, and LYFGENIA, as well as any future approved products and the timing or success thereof, including expectations regarding our network of qualified treatment centers;
•
the initiation, timing, progress and results of our preclinical and clinical studies, and our research and development programs;
•
our ability to advance"
"•
Among other potential adverse events, insertional oncogenesis is a significant risk of gene therapies using viral vectors that can integrate into the genome."
"The Company is a biotechnology company committed to researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector ("LVV") gene addition platform."
"These forward-looking statements include, but are not limited to, statements about:
•
our plans and expectations regarding our commercialization activities for SKYSONA, ZYNTEGLO, and LYFGENIA, as well as any future approved products and the timing or success thereof, including expectations regarding our network of qualified treatment centers;
•
the initiation, timing, progress and results of our preclinical and clinical studies, and our research and development programs;
•
our ability to advance"
"•
Among other potential adverse events, insertional oncogenesis is a significant risk of gene therapies using viral vectors that can integrate into the genome."
"The Company is a biotechnology company committed to researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector ("LVV") gene addition platform."
"These forward-looking statements include, but are not limited to, statements about:
•
our plans and expectations regarding our commercialization activities for SKYSONA, ZYNTEGLO, and LYFGENIA, as well as any future approved products and the timing or success thereof, including expectations regarding our network of qualified treatment centers;
•
the initiation, timing, progress and results of our preclinical and clinical studies, and our research and development programs;
•
our ability to advance"
"•
Among other potential adverse events, insertional oncogenesis is a significant risk of gene therapies using viral vectors that can integrate into the genome."
"The Company is a biotechnology company committed to researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector ("LVV") gene addition platform."
"Generally Accepted Accounting Principles (“US GAAP”) in connection with the Company's accounting for lease arrangements, including certain arrangements with contract manufacturing organizations (“CMOs”) and a contract testing organization (“CTO”) that are deemed to contain one or more leases for accounting purposes."
"These forward-looking statements include, but are not limited to, statements about:
•
our plans and expectations regarding our commercialization activities for SKYSONA, ZYNTEGLO, and LYFGENIA, as well as any future approved products and the timing or success thereof, including expectations regarding our network of qualified treatment centers;
•
the initiation, timing, progress and results of our preclinical and clinical studies, and our research and development programs;
•
our ability to advance"
"•
Among other potential adverse events, insertional oncogenesis is a significant risk of gene therapies using viral vectors that can integrate into the genome."
Source: SEC EDGAR · Retrieved Apr 05, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 92.2
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.2
CAR-T, Cell Therapy, AAV, Lentiviral
OmniaBio
Hamilton, ON
Signal Score: 79.5
AAV, Lentiviral, CAR-T, Cell Therapy
Lonza
Basel, Switzerland
Signal Score: 78.6
AAV, Lentiviral, Cell Therapy, mRNA
NecstGen
Leiden, NL
Signal Score: 78.1
AAV, Lentiviral, Cell Therapy